Roberto Rivera-Luna

Roberto Rivera-Luna

Auto-generated profile, based on publicly available information

Roberto Rivera-Luna

Research Direction, National Institute of Pediatrics, Mexico City 04530, Mexico

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2021 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
MZMarta Zapata-Tarrés
Marta Zapata-Tarrés
JBJuan Carlos Balandrán
Juan Carlos Balandrán
RRRoberto Rivera-Luna
Roberto Rivera-Luna
RPRosana Pelayo
Rosana Pelayo

30 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
RRRoberto Rivera-Luna
Roberto Rivera-Luna
PPPatricia Perez-Vera
Patricia Perez-Vera
CGCesar Galvan-Diaz
Cesar Galvan-Diaz
LVLiliana Velasco-Hidalgo
Liliana Velasco-Hidalgo
AOAlberto Olaya-Vargas
Alberto Olaya-Vargas
JPJesus Ponce-Cruz
Jesus Ponce-Cruz
Acute lymphoblastic leukemia (ALL) is the most common malignancy among Mexican and Hispanic children and the first cause of death by disease in Mexico. We propose a “triple-hit” explanation for the survival gap affecting this population. The first hit can be attributed to epidemiology and social, cultural, and economic burdens. The second hit refers to cancer biology, with a high incidence of unfavorable genetic characteristics associated with an unfavorable response to treatment and, subsequently, poor survival. Finally, the third hit relates to sub-optimal treatment and support. Society and culture, leukemia biology, and treatment approach limitations are key factors that should not be seen apart and must be considered comprehensively in any strategy to improve the prognosis of Mexican and Hispanic children with ALL.

10 January 2019 in Genes
Verified
Journal Article
Open access
PDF file
Sara FriasSara Frias
Sara Frias
Sandra RamosSandra Ramos
Sandra Ramos
CSConsuelo Salas
Consuelo Salas
BMBertha Molina
Bertha Molina
SSSILVIA SANCHEZ
SILVIA SANCHEZ
RRRoberto Rivera-Luna
Roberto Rivera-Luna
Anticancer regimens for Hodgkin lymphoma (HL) patients include highly genotoxic drugs that have been very successful in killing tumor cells and providing a 90% disease-free survival at five years. However, some of these treatments do not have a specific cell target, damaging both cancerous and normal cells. Thus, HL survivors have a high risk of developing new primary cancers, both hematologic and solid tumors, which have been related to treatment. Several studies have shown that after treatment, HL patients and survivors present persistent chromosomal instability, including nonclonal chromosomal aberrations. The frequency and type of chromosomal abnormalities appear to depend on the type of therapy and the cell type examined. For example, MOPP chemotherapy affects hematopoietic and germ stem cells leading to long-term genotoxic effects and azoospermia, while ABVD chemotherapy affects transiently sperm cells, with most of the patients showing recovery of spermatogenesis. Both regimens have long-term effects in somatic cells, presenting nonclonal chromosomal aberrations and genomic chaos in a fraction of noncancerous cells. This is a source of karyotypic heterogeneity that could eventually generate a more stable population acquiring clonal chromosomal aberrations and leading towards the development of a new cancer.

Verified
Journal Article
Open access
PDF file
DADANIEL ALEJANDRO MARTINEZ ANAYA
DANIEL ALEJANDRO MARTINEZ ANAYA
DLDafné Linda Moreno Lorenzana
Dafné Linda Moreno Lorenzana
ARAdriana Reyes-León
Adriana Reyes-León
UJUlises E Juárez-Figueroa
Ulises E Juárez-Figueroa
Michael DeanMichael Dean
Michael Dean
PPPatricia Pérez-Vera
Patricia Pérez-Vera
Ph-like subtypes with CRLF2 abnormalities are frequent among Hispano–Latino children with pre-B ALL. Therefore, there is solid ground to suggest that this subtype is frequent in Mexican patients. The genomic complexity of Ph-like subtype constitutes a challenge for diagnosis, as it requires diverse genomic methodologies that are not widely available in diagnostic centers in Mexico. Here, we propose a diagnostic strategy for Ph-like ALL in accordance with our local capacity. Pre-B ALL patients without recurrent gene fusions (104) were classified using a gene-expression profile based on Ph-like signature genes analyzed by qRT-PCR. The expressions of the CRLF2 transcript and protein were determined by qRT-PCR and flow cytometry. The P2RY8::CRLF2, IGH::CRLF2, ABL1/2 rearrangements, and Ik6 isoform were screened using RT-PCR and FISH. Surrogate markers of Jak2-Stat5/Abl/Ras pathways were analyzed by phosphoflow. Mutations in relevant kinases/transcription factors genes in Ph-like were assessed by target-specific NGS. A total of 40 patients (38.5%) were classified as Ph-like; of these, 36 had abnormalities associated with Jak2-Stat5 and 4 had Abl. The rearrangements IGH::CRLF2,P2RY8::CRLF2, and iAMP21 were particularly frequent. We propose a strategy for the detection of Ph-like patients, by analyzing the overexpression/genetic lesions of CRLF2, the Abl phosphorylation of surrogate markers confirmed by gene rearrangements, and Sanger sequencing.

16 September 2019 in Genes
Verified
Journal Article
Open access
PDF file
RRRicardo De la Rosa
Ricardo De la Rosa
VVVanessa Villegas-Ruíz
Vanessa Villegas-Ruíz
MCMarcela Concepción Caballero-Palacios
Marcela Concepción Caballero-Palacios
EPEleazar Israel Pérez-López
Eleazar Israel Pérez-López
CMChiharu Murata
Chiharu Murata
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
B-cell acute lymphoblastic leukemia is the most commonly diagnosed childhood malignancy worldwide; more than 50% of these cases are diagnosed in Mexico. Although the five-year survival rate is >80%, 30% of patients experience relapse with poor prognosis. Cancer-associated gene expression profiles have been identified in several malignancies, and some transcripts have been used to predict disease prognosis. The human transcriptome is incompletely elucidated; moreover, more than 80% of transcripts can be processed via alternative splicing (AS), which increases transcript and protein diversity. The human transcriptome is divided; coding RNA accounts for ~2%, and the remaining 98% is noncoding RNA. Noncoding RNA can undergo AS, promoting the diversity of noncoding transcripts. We designed specific primers to amplify previously reported alternative transcript variants of ZNF695 and showed that six ZNF695 transcript variants are co-expressed in cancer cell lines. The amplicons were sequenced and identified. Additionally, we analyzed the expression of these six transcript variants in bone marrow from B-cell acute lymphoblastic leukemia patients and observed that ZNF695 transcript variants one and three were the predominant variants expressed in leukemia. Moreover, our results showed the co-expression of coding and long noncoding RNA. Finally, we observed that long noncoding RNA ZNF695 expression predicted survival rates.

15 July 2008 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
PPPatricia Pérez-Vera
Patricia Pérez-Vera
CSConsuelo Salas
Consuelo Salas
OROreth Montero Ruíz
Oreth Montero Ruíz
Sara FriasSara Frias
Sara Frias
GDGloria Dehesa
Gloria Dehesa
RRRoberto Rivera-Luna
Roberto Rivera-Luna